Effect Of Citicholine Co-Administration With Antiplatelet In Hospitalized Stroke

Ischemic Patients by Rochmawati, Ike Dhiah et al.




70 | Page ISSN: 2654-8364 Vol.2 No.2 Juni 2020
   Vol.2 No.2 Juni 2020 a g e  
 
Effect Of Citicholine Co-Administration With Antiplatelet In Hospitalized Stroke 
Ischemic Patients 
Ike Dhiah Rochmawati1, Dody Mulia Saputra1, Rosy Rahmawati1 
1Department of Clinical and Community Pharmacy, Faculty of Pharmacy,  
University of Surabaya, Surabaya 60293, Indonesia  
Email: ikedhiah@gmail.com  
 
ABSTRACT: Ischaemic stroke is a disease caused by the formation of thrombus 
or emboli in the cerebral artery. One of the most important medicines which 
analysed in several studies is Citicholine. The purpose of this study was to look at 
the effect of adding Citicholine with antiplatelets in Ischemic Stroke patients. The 
design used was an observational study with a retrospective approach. Patient 
demographics were analyzed descriptively. From the results of the study found 
100 patients used as research samples. Based on the patient's characteristics, the 
greatest percentage was obtained in female patients, aged> 55 years and with 
accompanying hypertension, diabetes mellitus. After statistical analysis, there was 
no difference between the length of stay of patients in different age groups. 
Citicholine has been shown to provide better outcomes, by looking at the 
outcomes of patients who are totally cured compared with patients who are 
partially cured, statistically significant. 
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 INTRODUCTION 
Stroke is a disorder of brain function that occurs suddenly with clinical and 
global clinical signs and symptoms that last for 24 hours or more and can cause 
death due to circulatory disorders . Stroke is still becoming global health probems 
in many countries , including Indonesia. Stroke have a high mortality rate as the 
third most common disease causing death in the world after heart disease and 
cancer. The percentage of patients who died from the attack first stroke was 18% 
to 37% and the percentage increasing into 62% to recurrent stroke attack The 
incidence of strokes tends to increase based on age at the age of 45-54 years 
by 16.7 %, at age 55-64 years by 33 %, and at age > 65 years by 
46.1%.1 Antiplatelet is indicated in all patients who first suffered 
Transient Ischemic Attack (TIA) and Ischemic stroke  to reduce  risk of recurrent  
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events. Antiplatelet aims to increase the speed of spontaneous recanalization and 
improved microvascular , which can be administered orally or intravenously.  
Giving oral antiplatelet can be either a single agent or a combination. Use of 
the antiplatelet can reduce risk relatively of stroke, myocardial infarction and 
death by 22%.2  
 Various studies on the effectiveness of the administration of antiplatelet 
therapy as a preventive therapy for recurrent stroke has been done, including 
CHARISMA trial (Clopidogrel and Aspirin 
Versus Aspirin Alone For the Prevention of Atherothrombotic Events) showing 
combination of aspirin and clopidogrel is not more effective than aspirin alone in 
decreasing incidence of stroke, myocardial infarction or death due to 
cardiovascular.3 While the another study showing difference results of 
combination aspirin and clopidogrel has equal effectiveness  to aspirin in the 
restoration of the status of the health of visits based on the calculation of NIHSS 
(National Institute Of Health Stroke Scale). The results of  the 
study: Antiplatelet treatment for prevention of cerebrovascular events in patient w
ith vascular disease, systematic review and meta analysis states that 
the combination therapy of aspirin and clopidogrel is effective reducing risk of 
ischemic stroke compared to single aspirin by 20%.4 Neuroprotectants play a 
major role in reducing the number of disability and death in ischemic stroke 
patients. Neuroprotectant is one of stroke therapy aimed to reduce cell damage 
due to obstruction of blood flow that supplies oxygen.5 A neuroprotectant that is 
often used for ischemic stroke therapy is citicholine. Citicholine as a 
neuroprotectant at the neuronal level is to repair cell membranes by increasing the 
synthesis of phosphatidylcholine which is a major component of cell membranes 
in the brain. With the increased synthesis of phosphatidylcholine, this will affect 
the repair of cell membrane function that leads to cell repair.6 
Based on the study of Citicholine in Vascular Cognitive Impairment and 
Vascular Dementia After Stroke said that citicholine is a safe and recognized 
drug in various countries for use in ischemic stroke therapy. Experimental and  
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clinical studies have shown the possible effects of citicholine on neurorepair and 
neuroplastysis functions. Chronic treatment using citicholine can improve 
functional recovery and neurorepair potential shows that citicholine can improve 
nerve protection by increasing glutamate uptake. Neurotropic function has been 
shown to improve cognitive function.7 
Based on the previous data above, we did research to analyse the effect of 
citicholine co-administration with antiplatelet in stroke ischemic patients.  
    
Materials and Methods  
This research used observational retrospective design . The population used in this 
study were inpatients suffering from ischemic stroke in the period January 1 to 
April 30 2018. The process of data collection is done by recording patient data 
contained in the medical record. Parameters observed in this study are: patient 
characteristics (age , sex , comorbidities), characteristics of the drug (class of 
ntiplatelet therapy) and the class of other drugs), and length of stay (LOS). All the 
data will be analysed descriptively. Before taking patient’s data from patient 
medical record, the research team got the allowance permit from the Hospital. All 
the research team will keep the confidentiality of patient’s data in analysing, 
coding, and publishing this research. Because the method was retrospective, the  
ethic committe from the hospital did not ask any concerns, except the 
confidentiality 
 
Results and Discussions 
This study recruited 100 ischemic stroke patients during the research. 
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Table 1. Patient Characteristics 










































Based on Table 1 , the prevalence of ischemic stroke was higher in female 
patients than male patients. The incidence of ischemic stroke in men as many as 
44 people or 44%, while in women as many as 56 people or 56%. The highest 
prevalence of ischemic stroke most are in the age group ≥ 66 and 56-65 years 
with 31 patients (31 %)  and 30 patients (30%) respectively. The most 
common comorbidity found in this study was hypertension (47.78%). Diabetes 
mellitus was found as concomitant disease in 33 patients or 36.67%. Another  
comcomitant disease beside hypertension and diabetes mellitus was dyslipidemia. 
Dyslipidemia were also found in this study with  30 patients or 33.33%.  
Based on the result from previous studies, we cross tabulated data between 
citicholine administration, age, and length of stay (LOS). Chi-Square statistical 
analysis was done between age and length of stay in the citicholine group and the  
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value of P = 0.932. A P value > 0.05 indicates that can be interpreted that there is 
no significant difference between the different age levels and length of stay. In the 
group that did not use citicholine, a similar result was obtained, with a P value > 
0.05. From this result,  it can be said that there is no difference in length of stay 
between the citicholine group and the non-citicholine group. Because the length of 
stay in the two groups tends to be the same, which is 6-9 days. (table 2) 
When seen descriptively in the Citicholine group, the greatest number of patients 
had a length of stay of 8-9 days (21 patients), while in the Non-Citicholine group, 
the greatest number of patients had a length of stay of 6-7 days (27 patients). 
From the cross tabulation between citicholine administration and patient outcome, 
we can see that there was difference outcome in Citicholine administration.    43 
patients in Citicholine group showed well recovered while 14 patients showed 
partial recovery. The difference number of patients in different outcome showed 
statistically significant. (Table 2) 
 Gender differences are related to endogenous hormones and comorbid 
conditions such as hypertension. Hypertension is likely to be lower for woman 
before menopause beause the protective role of estrogen in blood vessels. As 
mentioned in patient characteristics, most of patients were elderly which related to 
menopause age. Different effects of hormones can be shown on platelet activity, 
which testosterone will increase platelet activity while estrogen will slow it down.  
.8 Another role of estrogen is as a vasodilatator of blood vessels so that cardiac 
blood flow becomes smooth and the heart gets adequate oxygen supply. This is 
what causes women to be genetically lower affected by ischemic stroke. The 
results of this study stated that 42 postmenopausal women or 72.41% were 
recorded as ischemic stroke patients and consequently the hormone estrogen had 
decreased dramatically, so postmenopausal women would have the same risk as 
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Table 2. Cross Tabulation Between Citicholine Administration, Age, and Length 
of Stay (LOS) in Stroke Ischemic Patients  
 
Length of Stay (LOS) 










Citicholine 11 4 5 16 21 57 0.932 
>66 years old 4 3 2 7 5 21  
36-45 years 
old 1 1 1 1 3 7 
 
46-55 years 
old 2 1 1 3 2 10 
 
56-65 years 
old 3 1 1 4 10 19 
 
Non 




>65 years old 2 1 1 5 1 10  
26-35 years 
old 








1 2 3 6 
 
46-55 years 









Total 12 4 6 41 27 100  
 
The results of the study are in line with the fact that older age is one of the 
risk factors for ischemic stroke, the risk of someone having a stroke 
increases after age above 55 years and that the level of the fatigue heart 
will increase with age.9 In hypertension, high blood pressure can accelerate the 
hardening of artery walls and result in the destruction of fat in smooth muscle 
cells so that it can accelerate the process of atherosclerosis through the effect of 
suppression of endothelial cells in the artery walls resulting in the formation of 




76 | Page ISSN: 2654-8364 Vol.2 No.2 Juni 2020
   Vol.2 No.2 Juni 2020 a g e  
 
blood vessel plaque faster. The higher the patient's blood pressure the greater the 
possibility of stroke.10 High level of blood sugar will accelerate atherosclerosis on 
small blood vessels and major blood vessels throughout the blood vessels, 
including the blood vessels of the brain and heart, it will cause 
expand infarction (cell death) due to the formation of lactic acid as a result of 
glucose metabolism and anaerobes condition will damage brain tissue.10 
Abnormalities in lipid profile are one of risk factors 
of atherosclerosis. Dyslipidemia can lead to endothelial dysfunction. Endothelial 
dyfunction can be related with imbalance function of endothelial cells, between 
aggregation and thrombotic state. Atherosclerosis is a change in arterial walls 
characterized by accumulation of extra cell lipids which results in thickening and 
stiffness of the arteries. Thickening of the arteries caused by fat deposits due 
to extra cells causes ischemia in the tissues to infarction .  
Citicoline is an endogenous component that is one of the keys in the 
phosphtidylcholine biosynthesis process.11,12 Citicholine is a type of drug that is 
classified as neuroprotectant. Neuroprotectants are a class of drugs that can slow 
down the existence of injuries or injuries both molecularly and biochemically. The 
existence of ischemic conditions can trigger brain damage, and this process can be 
inhibited or slowed down by neuroprotectants.13 Citicholine can be given with 500 
mg/ml twice daily until 1000 mg daily. Several studies found citicholine with 
dose 500 mg, 1000 mg, and 2000 mg mg, 1000 mg dan 2000 mg daily showed 
outcome significantly when compared with placebo, but different result showed 
by another study thatfound citicholine didn’t give different effectiveness 
significantly compared with placebo.1 
 The length of stay of a patient in the hospital can be influenced by several 
factors, in particular the condition of the accompanying disease and the severity of  
the patient's disease. The higher the severity of the patient's disease, the longer the 
patient will be hospitalized. So is the case with concomitant diseases. The more 
comorbidities that are owned by the patient will cause the patient's condition to be  
more complicated which can increase the risk of complications, it will increase the 
length of stay of the patient in the hospital. 
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 From the review about the effect of citicholine in Acute Ischemic Stroke 
patients, found that Citicholine relatively safe. The most beneficial effect of 
Citicholine will be found in less severe stroke (NIHSS score <14), elderly patients 
(>70 years), and patients who didn’t get recombinant tissue plasminogen 
activator.15  The mechanism of action of citicholine is repairing nerve membrane 
damage through phosphatidylcholine synthesis. Phosphatidylcholine itself is a 
major component of cell membranes, especially in the brain. Synthesis of 
phosphatidylcholine is increased because of the presence of citicholine,  which 
has an effect on cell repair.7 If rapid cell repair occurs, the healing process in 
stroke patients is faster, thus shortening the length of stay. But in this study did 
not get the expected results. The length of stay in the citicholine group was not 
significantly different. Some factors may be contributed in this result, such as 
comorbid conditions from each patient that may be worsening condition and make 
further length of stay (LOS). Citicholine was given orally at doses of 500, 1000, 
and 2000 mg given within 24 hours of the initial symptoms showing evidence of 
the success of 1,3722 patients in 4 clinical trials conducted in the United States. 
Citicholine can improve neurological function and recovery function. When 
compared with patients given placebo, ischemic stroke patients who were given 
citicholine were more likely to have improved neurological function based on the 
NIHSS and Barthel index of placebo by 21% and citicholine 33%.16 
 The results of this study indicate the significance of Citicholine 
administration by looking at patient recovery outcomes. If analyzed statistically, 
Citicholine is proven to provide benefits in the recovery process of patients, which 
is shown by the greater number of patients who experience good recovery 
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Table 3. Cross Tabulation Among Citicholine Administration, Age, and Outcome 
in Stroke Ischemic Patients 
Age (Years) Outcome P 
value Partial recovery Well recovery Total 
Citicholine 14 43 57 0.007 
>65  3 16 19  
36-45  0 5 5  
46-55  6 3 9  
56-65  3 16 19  
Non Citicholine 17 26 43 0.266 
>65 3 6 9  
26-35  2 0 2  
36-45 2 3 5  
46-55 5 6 11  
56-65  3 8 11  
Total 31 69 100  
 
 This is in line with the results of previous studies that explain the 
mechanism of action of Citicholine in terms of improving neurological function 
when measured using the Barthel index and NIHSS. The results of this study are 
slightly different from what was found by the ICTUS study. In the ICTUS study, 
citicholine made no difference in global recovery for 90 days compared to placebo. 
Some things that might make a difference are the characteristics of patients in the 
ICTUS study having a more severe stroke with an NIHSS value of around 14-15.14 
In stroke modeling studies, natural spontaneous function improvement actually 
occurs but improvement in ischemic stroke patients can occur for three months, 
with a note that neurological improvement also occurs. The neurological 
improvement in question includes not only repair of damaged neurons, but also an  
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increase in angiogenesis, as well as brain plasticity in both neurons and 
synaptics.17-19 In addition to providing neuroprotective effects, Citicholine can 
also provide neurological repair effects. Citicholine based on the results of 
previous studies, is proven to provide neurological improvement through several 
mechanisms, namely: inhibition of the process of apoptosis, increased 




Citicholine give better outcomes in stroke ischemic patients. The outcomes 
measured as well recovered when patients left the hospital.  
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